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Introduction
Parkinson’s disease (PD) is the most common neurodegener-
ative movement disorder with several disease-causing genes 
now identified. More recently an association between early-
onset Parkinson’s disease (EOPD) and deletions involving 
the 22q11.2 chromosomal region (22q11.2 deletion syn-
drome, 22q11.2DS) has been described. This represents one 
of the most common interstitial deletion syndromes (1 in 
4000 live births), and spans a 1.5–3 Mb region. 22q11.2DS 
is a heterogenous clinical syndrome involving neurodevel-
opmental, psychiatric, cardiac, immunological, and endo-
crinological abnormalities, with an autosomal dominant 
inheritance pattern, although many reported cases repre-
sent de novo mutations. The area of interest contains ~ 52 
genes, none of which have been previously linked to PD. 
The papers discussed below provide evidence of a potential 
association between 22q11.2DS and EOPD, and further seek 
to delineate the characteristic clinical features of this group.
Association between early‑onset Parkinson 
disease and 22q11.2 deletion syndrome
Identification of a novel genetic form of Parkinson 
disease and its clinical implications
Butcher et al. were the first to build on anecdotal evidence 
of an increased incidence of PD in those with 22q11.2DS. 
Their systematic assessment involved: (1) determining 
the frequency of PD amongst a cohort of individuals with 
22q11.2DS, (2) genetic screening for the 22q11.2 deletion 
in individuals diagnosed with young-onset PD, and (3) post-
mortem brain tissue analysis of individuals diagnosed with 
22q11.2DS and PD during life to determine whether the his-
topathological changes mirrored those seen in idiopathic PD.
Initial analysis involved clinical data from a large adult 
Canadian cohort identified as having a hemizygous 22q11.2 
deletion (n = 159). Recruitment was biased towards the 
younger and more severe end of the phenotypic spectrum, 
with individuals recruited via congenital, cardiac, psychi-
atric and genetic services, and ranging in age between 18 
and 68.6 years. They sought to identify the number of indi-
viduals with a confirmed clinical diagnosis of PD, demon-
strating a significantly higher rate compared to the general 
population (standardised morbidity ratio = 69.7; 95% CI 
19.0–178.5). Four patients were identified with early onset 
features (39–48 years), with a typical motor clinical pheno-
type, treatment response, and time course to that seen in idi-
opathic PD. There was evidence of lateralised motor signs in 
2/4 (50%), and all responded to treatment with dopaminergic 
therapy. Three of these patients had previously been treated 
with antipsychotic medication, with this contributing to an 
estimated delay in diagnosis of up to 10 years. There was 
no family history of PD in any of the cases, and screening 
for LRRK2, PARK2, PARK7, PINK1, and SNCA gene muta-
tions was negative. In the overall cohort only one patient was 
> 65 years, and therefore, it remains possible that further 
individuals will develop PD later in life.
Of the original cohort of 159, 18 individuals had died 
at the time of data analysis, with post-mortem data avail-
able for six, three of whom had a clinical diagnosis of PD 
in life. Neuropathological findings were compared between 
PD and 22q11.2DS (n = 3), 22q11.2DS alone (n = 3), and 
age-and sex-matched control group (n = 10). These results 
demonstrated histopathological changes consistent with that 
of idiopathic PD, namely loss of midbrain dopaminergic 
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neurons and extensive nigral degeneration, in all three 
cases of 22q11.2DS-associated PD. Of these, α-synuclein-
positive Lewy bodies were also present in two of the three 
cases (corresponding to Braak stages V and VI). Finally, one 
22q11.2DS case was identified after screening 225 patients 
with early-onset PD using quantitative polymerase chain 
reaction (qPCR) techniques. However, this patient was sub-
sequently identified to be patient 3 in the 22q11.2DS cohort.
Comment. This study was the first to demonstrate the 
potential link between 22q11.2DS and early-onset PD. Clini-
cal similarities to idiopathic PD included motor phenotype, 
response to Levodopa treatment and neuropathological find-
ings. However, the 22q11.2DS cohort was biased towards 
the more severe clinical phenotypic and younger age of the 
disorder spectrum, potentially not accurately reflecting PD 
prevalence amongst this group. Additionally, genetic test-
ing of the EOPD revealed only a single previously known 
case, potentially raising doubts as to the frequency of this 
genetic aetiology amongst those presenting initially with a 
PD motor phenotype.
Butcher et al., JAMA Neurol 2013; 70(11): 1359–1366.
Deletions at 22q11.2 in idiopathic Parkinson’s 
disease: a combined analysis of genome‑wide 
association data
This study took the opposite approach to that of the first 
paper, estimating the frequency of 22q11.2DS in a large 
cohort of individuals with PD. In total, 9,387 PD patients 
and 13,863 controls were analysed from four independently 
recruited cohorts: (1) the UK Wellcome Trust Case Control 
Consortium 2 Parkinson’s Disease (n = 1592), (2) Dutch 
Parkinson’s Disease Genetics Consortium (n = 740), (3) 
US National Institute on Aging (NIA) (n = 593), and (4) the 
International Parkinson’s Disease Genomics Consortium 
(IPDGC NeuroX) (n = 6462). All recruited participants ful-
filled UK Brain Bank Criteria for the diagnosis of PD, and 
were negative when screened for mutations in known PD-
causing genes.
A 22q11.2 deletion was identified in eight unrelated indi-
viduals, from three of the four cohorts, all spanning > 3 Mb, 
with none identified in the control sample. Interestingly, 
located within the proximal region of the deleted region, 
is the COMT gene, implicated in dopamine metabolism. 
Mean age at onset of parkinsonian symptoms was 18 years 
younger in those with a 22q11.2 deletion compared to 
those without (42 and 60 years, respectively) with a sig-
nificantly higher frequency of 22q11.2 deletions in those 
with EOPD (five patients ≤ 45 years, p < 0.0001) as well as 
a smaller association in those with late onset motor symp-
toms (three patients > 45 years, p = 0.016). Four had abnor-
mal dopamine transporter imaging (DAT scan), suggesting 
that the observed clinical parkinsonian features were due 
to PD, rather than prior neuroleptic medication, although 
detailed medication usage was absent in the majority. Of the 
available data, PD patients with 22q11.2DS demonstrated 
symptomatic improvement to dopaminergic therapy (n = 5), 
although tended towards faster symptomatic deterioration 
and had an early onset of drug-induced dyskinesias.
Comment. This study identified eight patients with 
22q11.2DS-associated PD, but was limited by its cross-
sectional, retrospective nature, and at times limited clinical 
data. A larger factor however, was the inconsistent exclu-
sion of known PD gene mutations; no data was reported in 
the Dutch study, only PARK2 and PINK1 mutations were 
screened for in the UK and US-NIA studies. The lack of 
major cardiac abnormality or schizophrenia in the PD group, 
and the absence of deletions seen in the control group poten-
tially indicate recruitment bias, influencing the associations 
identified.
Mok et al., Lancet Neurol 2016; 15:585–596.
Typical features of Parkinson disease and diagnostic 
challenges with microdeletion 22q11.2
This international observational study is the largest to sum-
marise the clinical features and neuroimaging findings of 45 
individuals with 22q11.2DS-associated PD. A total of 23 
publications involving 35 patients were identified. Clinical 
information was collected using standardised data forms, 
either from medical records or direct assessments (26/35, 
74.3%), with 10 further unpublished cases from the Inter-
national Consortium on Brain and Behaviour in 22q11.2DS.
Overall, 22q11.2DS-associated PD was more frequently 
observed in men (71.1%), mean age at onset of motor 
symptoms was 39.5 years, with 71% of the patients meeting 
EOPD criteria. Sixteen patients (84%) had a de novo dele-
tion, with mean age at PD diagnosis being 42 years. Individ-
uals with a history of antipsychotic use had a longer median 
time to PD diagnosis (5 years) compared to antipsychotic-
naive patients (1 year). As seen in idiopathic PD, patients 
ultimately developed increased gait impairment and bulbar 
dysfunction, and all patients demonstrated rigidity in the 
final assessment. New onset of neuropsychiatric symptoms 
was thought to be related to antiparkinsonian medications in 
eight patients, however, one cannot exclude PD progression, 
or as a result of the deletion syndrome. Early-onset dystonia, 
intellectual disability, schizophrenia and seizures were other 
features more often seen in 22q11.2DS-associated PD.
The majority of patients demonstrated a positive response 
to levodopa medication (28/30, 93%) and dopamine agonists 
(12/14, 86%). Five patients received Deep Brain Stimulation, 
with symptomatic improvement in four. Seven patients had 
died at the time of data analysis, with a median age at death 
of 56 years. Presynaptic dopaminergic imaging information 
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was available for 20/35 patients (44.4%). Eighteen of these 
were DAT scans, with 17 demonstrating reduced (con-
tralateral or bilateral) striatal binding. The remaining two 
patients underwent PET and 11C-dihydrotetrabenazine 
([11C]DTBZ) scans, one of which demonstrated reduced 
striatal binding.
Comment. Although this study represents an extensive 
international collaborative effort, and the largest data col-
lection to date, the authors identify a number of potential 
limitations: potential publication bias given the method of 
case identification, under-representation of parkinsonian 
symptoms given the younger age of the cohort, incom-
plete data sets and risk of mis-interpretation of case note 
documentation. These highlighted the need for ongoing 
prospective recruitment of cases on an international basis, 
with longitudinal data collection, and equal emphasis on 
non-motor as well as motor information.
Boot et al., Neurology 2018; 90:e2059–2067.
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